(Q37378994)

20 August 2017

1 reference

title

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients (English)

1 reference

20 August 2017

1 reference

Christine M Walko

1

1 reference

20 August 2017

Howard McLeod

series ordinal

2

1 reference

20 August 2017

publication date

27 January 2009

1 reference

Nature Clinical Practice Oncology

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

153-162

1 reference

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1303

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1303

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1303

The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1303

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

12 December 2020

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

1 reference

12 December 2020

Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.

1 reference

12 December 2020

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial

1 reference

12 December 2020

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

12 December 2020

The use of surface area as a basis for establishing normal blood volume

1 reference

12 December 2020

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

12 December 2020

Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C

1 reference

12 December 2020

Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia

1 reference

12 December 2020

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

12 December 2020

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

1 reference

12 December 2020

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

12 December 2020

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians

1 reference

12 December 2020

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

1 reference

12 December 2020

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

1 reference

12 December 2020

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

12 December 2020

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports

1 reference

12 December 2020

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

12 December 2020

Systemic therapy for metastatic colorectal cancer: current options, current evidence

1 reference

12 December 2020

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

12 December 2020

Quantitative prediction of drug toxicity in humans from toxicology in small and large animals

1 reference

12 December 2020

Tamoxifen in the treatment of breast cancer

1 reference

12 December 2020

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

12 December 2020

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

1 reference

12 December 2020

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

12 December 2020

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

12 December 2020

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

1 reference

12 December 2020

Adjuvant endocrine therapy for premenopausal women with early breast cancer.

1 reference

12 December 2020

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

1 reference

12 December 2020

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

1 reference

12 December 2020

Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia

1 reference

12 December 2020

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients

1 reference

12 December 2020

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

12 December 2020

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

12 December 2020

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

1 reference

12 December 2020

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

12 December 2020

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

1 reference

12 December 2020

A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FNCPONC1303

7 January 2021

inferred from DOI database lookup

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

12 December 2020

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

12 December 2020

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

12 December 2020

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

12 December 2020

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

12 December 2020

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

12 December 2020

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

12 December 2020

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

12 December 2020

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

12 December 2020

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

1 reference

12 December 2020

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

12 December 2020

Identifiers

DOI

10.1038/NCPONC1303

1 reference

release_ogpr7wg5e5bjdipfcebme7vjt4

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ogpr7wg5e5bjdipfcebme7vjt4

24 November 2022

mapped directly with Wikidata item

1 reference